These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37595260)

  • 1. Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.
    Ngo C; Fried W; Aliyari S; Feng J; Qin C; Zhang S; Yang H; Shanaa J; Feng P; Cheng G; Chen XS; Zhang C
    J Med Chem; 2023 Sep; 66(17):12237-12248. PubMed ID: 37595260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
    Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
    Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.
    Brewitz L; Dumjahn L; Zhao Y; Owen CD; Laidlaw SM; Malla TR; Nguyen D; Lukacik P; Salah E; Crawshaw AD; Warren AJ; Trincao J; Strain-Damerell C; Carroll MW; Walsh MA; Schofield CJ
    J Med Chem; 2023 Feb; 66(4):2663-2680. PubMed ID: 36757959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
    Tan B; Joyce R; Tan H; Hu Y; Wang J
    Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazolidinone-based peptidomimetic SARS-CoV-2 M
    Jelisejevs D; Bula AL; Kinena L
    Bioorg Med Chem Lett; 2023 Nov; 96():129530. PubMed ID: 37866713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of highly potent covalent SARS-CoV-2 3CL
    Zhang FM; Huang T; Wang F; Zhang GS; Liu D; Dai J; Zhang JW; Li QH; Lin GQ; Gao D; Zhao J; Tian P
    Eur J Med Chem; 2023 Nov; 260():115721. PubMed ID: 37598484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fast and Effective Prediction of the Absolute Binding Free Energies of Covalent Inhibitors of SARS-CoV-2 Main Protease and 20S Proteasome.
    Zhou J; Saha A; Huang Z; Warshel A
    J Am Chem Soc; 2022 May; 144(17):7568-7572. PubMed ID: 35436404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
    Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
    J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman DD; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PC; Cho CD; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    bioRxiv; 2023 Apr; ():. PubMed ID: 37090597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.
    Steuten K; Kim H; Widen JC; Babin BM; Onguka O; Lovell S; Bolgi O; Cerikan B; Neufeldt CJ; Cortese M; Muir RK; Bennett JM; Geiss-Friedlander R; Peters C; Bartenschlager R; Bogyo M
    ACS Infect Dis; 2021 Jun; 7(6):1457-1468. PubMed ID: 33570381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors.
    Previti S; Ettari R; Calcaterra E; Di Maro S; Hammerschmidt SJ; Müller C; Ziebuhr J; Schirmeister T; Cosconati S; Zappalà M
    Eur J Med Chem; 2023 Feb; 247():115021. PubMed ID: 36549112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
    Hicks EG; Kandel SE; Lampe JN
    Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 M
    Kattula B; Reddi B; Jangam A; Naik L; Adimoolam BM; Vavilapalli S; Are S; Thota JR; Jadav SS; Arifuddin M; Addlagatta A
    Int J Biol Macromol; 2023 Jul; 242(Pt 2):124772. PubMed ID: 37172706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.
    Su H; Yao S; Zhao W; Zhang Y; Liu J; Shao Q; Wang Q; Li M; Xie H; Shang W; Ke C; Feng L; Jiang X; Shen J; Xiao G; Jiang H; Zhang L; Ye Y; Xu Y
    Nat Commun; 2021 Jun; 12(1):3623. PubMed ID: 34131140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
    La Monica G; Bono A; Lauria A; Martorana A
    J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulforaphane is a reversible covalent inhibitor of 3-chymotrypsin-like protease of SARS-CoV-2.
    Chen Z; Du R; Cooper L; Achi JG; Dong M; Ran Y; Zhang J; Zhan P; Rong L; Cui Q
    J Med Virol; 2023 Mar; 95(3):e28609. PubMed ID: 36840402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.